SEC For	m 4 FORM	4			TES			юіті				хсн/		<u> </u>		SION				
				, 915	TATES SECURITIES AND EXCHANGE COMMIS Washington, D.C. 20549												OMB APPROVAL			
Check Section obligat Instruc	ed purs	Pursuant to Section 16(a) of the Securities Exchange Act of 1934											HIP OMB Number Estimated ave hours per resp			3235-0287 n 0.5				
1. Name and Address of Reporting Person [*] Doyle Ramona (Last) (First) (Middle)						RECURSION PHARMACEUTICALS, INC. [RXRX]											5. Relationship of Reporting Perso (Check all applicable) Director X Officer (give title below) Chief Medical C			
C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET						3. Date of Earliest Transaction (Month/Day/Year) 03/31/2022														
(Street) SALT LAKE CITY (City) (State) (Zip)					4. lf	Line) X Fo											al or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting ferson			
		Tak	ole I - Nor	-Deriv	/ative	e Se	curit	ties A	cqu	ired, I	Disp	osed	of, or E	Bene	ficially	/ Owned				
1. Title of Security (Instr. 3) Date (Month/D						- 1	2A. Deemed Execution Date if any (Month/Day/Yea		e,	Code (Ins					5. Amou Securitie Beneficia Owned F Reported	es Form ally (D) Following (I) (I		: Direct r Indirect str. 4)	. Nature of ndirect Beneficial Ownership Instr. 4)	
										Code	v	Amount	t (A (D	(A) or (D)		Transact (Instr. 3 a	tion(s) and 4)			`
Class A Common Stock 03/31/					1/2022	/2022				М		9,07	9,072 A		\$2.48	121	121,942		D	
			Table II - I (f, or Be ible se			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				Expi	ate Exer iration D nth/Day/	ate		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie: Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exer	e rcisable	Expiration Date		Title	or Nu	nount mber Shares						
Stock Option (Right to Buy)	\$2.48	03/31/2022			М			9,072		(1)	12/	/30/2030	Class A Common Stock	66	59,356	\$0.00	669,35	56	D	
Stock Option (Right to Buy)	\$11.4									(2)	02/	/04/2032	Class A Common Stock	7	6,998		76,99	8	D	
Stock Option (Right to Buy)	\$11.4								02/0	04/2022	02/	/04/2032	Class A Common Stock	4	l,784		4,784	4	D	

Explanation of Responses:

1. Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

2. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Remarks:

<u>/s/ Jonathan Golightly,</u> attorney-in-fact

04/04/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.